前收市價 | 88.45 |
開市 | 88.45 |
買盤 | 71.65 |
賣出價 | 72.95 |
拍板 | 200.00 |
到期日 | 2024-09-20 |
今日波幅 | 88.40 - 88.45 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 3 |
Dow Jones biotech leader Amgen, along with streaming giant Netflix and Spotify, are in or near buy zones in today's stock market.
There's probably a big enough pie here for everyone to get a slice.
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-medi